Results 11 to 20 of about 123,267 (281)

Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly

Reports, 2020
This study aimed to identify the characteristics of patients with hemophilia B eligible for once-weekly treatment with Nonacog alfa. Methods: A survey was conducted in 14 Hemophilia (HCs) of Italy.
Dorina Cultrera, Raimondo De Cristofaro, Paola Giordano, Silvia Linari, Silvia Macchi, Renato Marino, Angelo Claudio Molinari, Angiola Rocino, Cristina Santoro, Piercarla Schinco, Sergio Siragusa, Giuseppe Tagariello, Annarita Tagliaferri, Ezio Zanon, Massimo Morfini   +14 more
doaj   +1 more source

Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy

European Journal of Medical Research, 2021
Background Bleeding is the most common complication of oral anticoagulants, due to inadequate dosing. Case presentation This report describes the clinical course of a patient who developed severe bleeding under therapy with phenprocoumon, despite an INR ...
Nils Mülling, Vivian Rosery, H. Christian Reinhardt, Maher Hanoun   +3 more
doaj   +1 more source

RENAL ALLOGENEIC TRANSPLANTATION IN PATIENT WITH HAEMOPHILIA B

Вестник трансплантологии и искусственных органов, 2014
We report the case of successful renal allogeneic transplantation and treatment in a 56-year-old patient with haemophilia B at Hematology Research Center. He has received replacement therapy by factor IX since 2010.
N. V. Purlo, R. B. Achmetshin, A. J. Bulanov, E. A. Likhacheva, L. S. Birjukova   +4 more
doaj   +1 more source

APTAMERS ARE NEW PHARMACOLOGICAL SUBSTANCES FOR THE DEVELOPMENT OF ANTICOAGULANTS

Атеротромбоз, 2017
A ptamers are a new class of oligonucleotide compounds capable of specific binding to various molecular targets and inhibiting their activity. Aptamers are selected from a library of randomly syn-thesized oligonucleotides (from 20 to 60 nucleotides long)
A. V. Mazurov, V. A. Spiridonova
doaj   +1 more source

Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B

Journal of Blood Medicine, 2023
Katsuyuki Fukutake,1,2 Kanae Togo,3 Linghua Xu,3 Leona E Markson,4 José Maria Jimenez Alvir,5 Ian Winburn,6 Toshiyuki Karumori3 1Laboratory Medicine, Tokyo Medical University, Shinjuku, Tokyo, Japan; 2Department of Blood Coagulation Diseases, Ogikubo ...
Fukutake K, Togo K, Xu L, Markson LE, Alvir JMJ, Winburn I, Karumori T   +6 more
doaj  

Gene Therapy and Hemophilia: Where Do We Go from Here?

Journal of Blood Medicine, 2022
Nancy S Bolous,1 Nidhi Bhatt,2 Nickhill Bhakta,1 Ellis J Neufeld,2 Andrew M Davidoff,3 Ulrike M Reiss2 1Department of Global Pediatric Medicine – St.
Bolous NS, Bhatt N, Bhakta N, Neufeld EJ, Davidoff AM, Reiss UM   +5 more
doaj  

“Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A Study of 276 Patients in Western India

Global Journal of Transfusion Medicine, 2019
Introduction: Hemophilia is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) in hemophilia A (HA) or factor IX (FIX) in hemophilia B (HB).
Sangita Darshan Shah, Tarak R Patel, Nidhi M Bhatnagar, Maitrey D Gajjar, Mamta Chintan Shah, Sujata Tripathi   +5 more
doaj   +1 more source

Blood coagulation parameters in fallow deer (Dama dama)

Veterinární Medicína, 2011
There are frequent reports from around the world of wild animals being poisoned with anticoagulants. Granulated baits can result in primary or secondary poisoning of non-target animals.
Z. Siroka, B. Krocilova, J. Pikula, H. Bandouchova, L. Peckova, F. Vitula   +5 more
doaj   +1 more source

Beware of Reversal of an Anticoagulated Patient with Factor IX in the Emergency Department: Case Report of a Medical-Legal Misadventure

Clinical Practice and Cases in Emergency Medicine, 2020
In this article we present a case of a patient who received reversal of anticoagulation therapy with factor IX in violation of hospital guidelines. As a direct result, myocardial infarction and ischemic stroke occurred, leaving the patient neurologically
Steven Gannon, David Bell, Kenneth Jackmiczyk, Gregory Moore   +3 more
doaj   +1 more source

Efficacy of a high-purity factor IX concentrate in hemophilia B patients undergoing surgery [PDF]

Revista Brasileira de Hematologia e Hemoterapia, 2002
A plasma derived, high purity, solvent-detergent treated and subsequently nanofiltered factor IX concentrate (BEMOFIL) was evaluated in 19 hemophilia B patients, including four with severe, thirteen with mild or moderate type of disease and two ...
Vesa Rasi, Freja Ebeling
doaj   +1 more source